ABIVAX Société Anonyme (Abivax SA) aktie
AAVXF
$71.26-54.74 (-43.44%)
Indlæser graf...
Abivax SA
Market Cap
$5,679,032,832
Åben76.80
Høj76.80
Lav71.26
Omsætning200
P/EN/A
Børsværdi5.68B
52-ugers høj133.40
52-ugers lav7.21
Gns. omsætning11
UdbytteN/A
Beta-0.19
EPS-5.37
Om ABIVAX Société Anonyme (Abivax SA) aktie
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Selskabsinformation
Børs: OTC Markets OTCPK (PNK)
Sektor: Sundhed
Industri: Bioteknologi
Adresse:
7-11 Boulevard Haussmann
75009 Paris, France
75009 Paris, France
Telefon: + 33 1 53 83 09 63
Hjemmeside: https://www.abivax.com
Analytikernes aktieanbefalinger
Denne oversigt giver et hurtigt indblik i, hvordan analytikere vurderer aktiens potentiale baseret på deres seneste analyser og kursmål.
Laveste kursmål
Gennemsnitligt kursmål
Median kursmål
Højeste kursmål